North Central London
Joint Formulary
 
back
8 Malignant disease and immunosuppression

The formulary for systemic anti-cancer treatments should be viewed alongside the 'National Cancer Drugs Fund list'

https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/

08-02-04 Other immunomodulating drugs

Cladribine tablets Mavenclad®
Restricted

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis
 

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF
Daratumumab injection
Restricted

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. 
    • See links below
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
Link  NICE TA454 (not recommended): Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Link  NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Link  NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
 

Restricted Drug View adult BNF  View SPC online  View childrens BNF  CDF
Dimethyl fumarate Tecfidera®
Restricted

DO NOT CONFUSE Tecfidera® AND Skilarence® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
    • Check MHRA Drugs Safety Updates
  • RFL:
    • As per NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA320: Dimethyl fumarate for multiple sclerosis
 

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Fingolimod
Formulary

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
    • Check MHRA Drug Safety Updates
  • RFL:
    • As per NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
 

GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Lenalidomide 
Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. 
    • All prescriptions must be accompanied by a prescription authorisation form
    • See links below
    • Check MHRA Drug Safety Update
  • RFL:
    • As per NICE TAs
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
    • Patient, prescriber and supplying pharmacy must comply with a pregnancy prevention programme
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
Link  NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
Link  NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Link  NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
Link  NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
Link  NICE TA603 (terminated appraisal): Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma
 

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD  CDF
Ocrelizumab injection
Formulary

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Link  NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
 

View adult BNF  View SPC online  View childrens BNF
Pomalidomide
Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Check MHRA Drugs Safety Updates
  • RFL:
    • As per NICE TAs
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).
    • Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
      Patient, prescriber and supplying pharmacy must comply with a pregnancy prevention programme
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See links below
Link  NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Link  NICE TA602 (terminated appraisal): Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma
 

Restricted Drug View adult BNF  View SPC online  View childrens BNF  HCD  CDF
Teriflunomide
Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA303: Teriflunomide for relapsing remitting MS
Link  NICE TA405:Trifluridine–tipiracil for previously treated metastatic colorectal cancer
 

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Thalidomide
Restricted

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Check MHRA Drug Safety Alerts
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
    • Patient, prescriber and supplying pharmacy must comply with a pregnancy prevention programme
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • The use of thalidomide is restricted to Consultant Haematologists for the treatment of end-stage myeloma.
Link  NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
 

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Cediranib Recentin®
Non Formulary

View adult BNF  View SPC online  View childrens BNF
Cobimetinib
Non Formulary
Link  NICE TA414 (not recommended): Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
 

View adult BNF  View SPC online  View childrens BNF
Dinutuximab beta injection
Non Formulary

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA538: Dinutuximab beta for treating neuroblastoma
 

View adult BNF  View SPC online  View childrens BNF
Pemrolizumab Keytruda®
Non Formulary

View adult BNF  View SPC online  View childrens BNF
Siltuximab
Non Formulary

View adult BNF  View SPC online  View childrens BNF